0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Letter to the Editor   |    
Elevated Clozapine Plasma Level With Lamotrigine
MONIQUE KOSSEN, M.D.; JEAN PAUL SELTEN, M.D., PH.D.; RENÉ S. KAHN, M.D., PH.D.
Am J Psychiatry 2001;158:1930-1930. doi:10.1176/appi.ajp.158.11.1930

To the Editor: Clozapine is effective in treating patients with schizophrenia who are unresponsive to, or intolerant of, classic antipsychotics (1). However, a substantial proportion of patients fail to respond to clozapine or respond only partially. Durson et al. (2) reported substantial improvement in six patients when lamotrigine, an anticonvulsant and mood stabilizer, was added to clozapine therapy in a dose of 125–250 mg/day.

Because of the promising results of this study, we prescribed lamotrigine to Mr. A, a 35-year-old outpatient. He had been taking clozapine, 400 mg/day, for 3 years and had responded partially to treatment. His plasma levels of clozapine (in six assays over 3 years) had been stable (between 300 and 500 μg/liter, measured 12 hours after a dose was taken). When lamotrigine treatment began, his clozapine plasma level was 350 μg/liter.

His lamotrigine dose was titrated up to 100 mg/day in steps of 25 mg every 2 weeks. When Mr. A had taken 100 mg/day for 2 weeks, he complained of dizziness and sedation. When we determined his plasma level of clozapine, it was found to have tripled, to 1020 μg/liter. Since Mr. A showed no clinical improvement, his lamotrigine dose was tapered over a period of 2 weeks. At the end of this period, his clozapine plasma level had returned to a therapeutic level of 450 μg/liter.

How can we explain the tripling of the patient’s clozapine plasma level during his use of lamotrigine? It is highly unlikely that the patient had taken an overdose; he was certainly not suicidal. We searched for a pharmacokinetic explanation. Drugs that are highly protein bound (e.g., warfarin) can influence clozapine plasma levels, but lamotrigine is not. The metabolism of clozapine occurs mainly in the liver and is dependent on cytochrome P-450. The P-450 isoenzymes responsible for the metabolism of clozapine have not yet been fully characterized, but CYP1A2 appears to contribute to a major extent (3). Some drugs (e.g., fluoxetine and fluvoxamine) can interfere with the metabolism of clozapine by inhibiting CYP1A2 (4). Lamotrigine, however, is believed to be free of these enzyme interactions. It is metabolized in the liver by glucuronidation and eliminated almost entirely by the kidneys (5).

Consequently, we have no explanation for the great increase in the patient’s plasma level of clozapine during concomitant use of lamotrigine. When lamotrigine is added to clozapine, clinicians should be aware of this possibility.

Wagstaff J, Bryson HM: Clozapine. Drugs  1990; 40:722-747
[PubMed]
[CrossRef]
 
Dursun SM, McIntosh D, Milliken H: Clozapine plus lamotrigine in treatment-resistant schizophrenia (letter). Arch Gen Psychiatry  1999; 56:950
[PubMed]
[CrossRef]
 
Bertilsson L, Carrillo JA, Dahl ML: Clozapine disposition covaries with CYP1A2 activity. Br J Clin Pharmacol  1994; 38:471-473
[PubMed]
 
Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Harter S, Hiemke C: Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors. J Clin Psychopharmacol  1998; 18:2-9
[PubMed]
[CrossRef]
 
Elwes RD, Binnie CD: Clinical pharmacokinetics of newer antiepileptic drugs: lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet  1996; 30:403-415
[PubMed]
[CrossRef]
 
+

References

Wagstaff J, Bryson HM: Clozapine. Drugs  1990; 40:722-747
[PubMed]
[CrossRef]
 
Dursun SM, McIntosh D, Milliken H: Clozapine plus lamotrigine in treatment-resistant schizophrenia (letter). Arch Gen Psychiatry  1999; 56:950
[PubMed]
[CrossRef]
 
Bertilsson L, Carrillo JA, Dahl ML: Clozapine disposition covaries with CYP1A2 activity. Br J Clin Pharmacol  1994; 38:471-473
[PubMed]
 
Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Harter S, Hiemke C: Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors. J Clin Psychopharmacol  1998; 18:2-9
[PubMed]
[CrossRef]
 
Elwes RD, Binnie CD: Clinical pharmacokinetics of newer antiepileptic drugs: lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet  1996; 30:403-415
[PubMed]
[CrossRef]
 
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 5.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 23.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 37.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 34.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles
Optimizing clozapine treatment. Acta Psychiatr Scand 2011;123(6):411-22.